当前位置:药药网 / 数据中心 / 儿科研究特征电子表格
Pomalyst
儿科标签批准日期
2020/11/20 0:00:00
特定指示/秒
Progressive or refractory CNS tumors
标签更改摘要
- Safety and effectiveness have not been established in pediatric patients.
- Safety and effectiveness were assessed but not established in two open-label studies: a dose escalation study in 25 pediatric patients aged 5 to < 17 years old was within the range observed in adult patients with MM but higher than the exposure observed in adult patients with KS.
- Information on PK parameters.
研究年龄
4 YEARS - 18 YEARS
5 YEARS - 20 YEARS
学习类型
Efficacy,Safety,Tolerability
Efficacy,Safety,Pharmacokinetic
研究设计
Multicenter,Parallel Group,Open-Label,Phase 2
Open-Label,Phase 1,Single-arm,Dose Escalation
国家
United States,France,Italy,Spain,United Kingdom
United States